Search

Displaying results 3271 - 3280 of 10000 in total
  1. Drug

    Antipyrine

    go.drugbank.com/drugs/DB01435
    Approved

    Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)

  2. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. … Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

  3. Drug

    Ephedrine

    go.drugbank.com/drugs/DB01364
    ApprovedInvestigational

    [L12972] Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists. … It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine

    Mixtures: COPHADYL-E COUGH LINCTUSProducts: T-drene 1, Ultra T-M - Tablet
  4. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    [A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias.

  5. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.

  6. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    , after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to the racemic mixture. … Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo.

  7. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.

  8. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues. … Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.

  9. Drug

    Gluconic Acid

    go.drugbank.com/drugs/DB13180
    ApprovedInvestigational

    Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

    Mixtures: INYECCION MULTIPLE DE ELECTROLITOS TIPO I, ELETTROLITICA DI REINTEGRAZIONE CON GLUCOSIO E SODIO GLUCONATO MONICO
  10. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).